News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

23andMe Invites Customers to Add Health and Drug Data to Stored Genetic Test Results, Encroaching on Markets Where Both Apple and Clinical Laboratories Generate Revenue

Combining consumers’ health data, including clinical laboratory test results, to genetic data for predispositions to chronic diseases could be key to developing targeted drugs and precision medicine treatments

Genetic testing company 23andMe is beta testing a method for combining customers’ private health data—including clinical laboratory test results and prescription drug usage—with their genetic data to create the largest database of its kind.

Such information—stored securely but accessible to 23andMe for sale to pharmaceutical companies for drug research and to diagnostics developers—would place 23andMe in a market position even Apple Health cannot claim.

Additionally, given the importance of clinical lab test data—which makes up more than 70% of a patient’s medical records—it’s reasonable to assume that innovative medical laboratories might consider 23andMe’s move a competitive threat to their own efforts to capitalize on combining lab test results with patients’ medical histories, drug profiles, and demographic data.

23andMe plans to use third-party medical network Human API to collect and manage the data. Involvement in the beta test is voluntary and currently only some of the genetic company’s customers are being invited to participate, CNBC reported.

Apple Healthcare, 23andMe, and Predicting Disease

The announcement did not go unnoticed by Apple, which has its own stake in the health data market. Apple Healthcare’s product line includes:

  • Mobile device apps for using at point-of-care in hospitals;
  • iPhone apps that let customers store and share their medical and pharmaceutical histories and be in contact with providers;
  • ResearchKit, which lets researchers build specialized apps for their medical research;
  • CareKit, which lets developers build specialized monitoring apps for patients with chronic conditions; and
  • Apple Watch, which doubles as a medical device for heart monitoring.

What Apple does not have is genetic data, which is an issue.

An Apple Insider post notes, “As structured, 23andMe’s system has advantages over Apple’s system including not just genetic data, but insights into risks for chronic disease.”

This is significant. The ability to predict a person’s predisposition to specific chronic diseases, such as cancer, is at the heart of Precision Medicine. Should this capability become not only viable and reliable but affordable as well, 23andMe could have a sizeable advantage in that aspect of the health data market.

Anne Wojcicki (above) is CEO and co-founder of 23andMe. The genetic company is inviting some of its customers to combine their medical information—including clinical laboratory test results and medication histories—with their stored genetic data. Customers would have access to the combined data and be able to share it with providers. In exchange, 23andMe gets to sell it to pharmaceutical companies and diagnostics developers. If successful and popular with the eight to 10-million people who have reportedly purchased its test kits, 23andMe could produce a significant source of revenue. (Photo copyright: Inc.)

Genetic Test Results Combined with Clinical Laboratory Test Results

23andMe is hopeful that after people receive their genetic test results, they will then elect to add their clinical laboratory results, medical histories, and prescription drug information to their accounts as well. 23andMe claims its goal is to provide customers with easy, integrated access to health data that is typically scattered across multiple systems, and to assist with medical research.

“It’s a clever move,” Ruby Gadelrab, former Vice President of Commercial Marketing at 23andMe who now provides consulting services to health tech companies, told CNBC. “For consumers, health data is fragmented, and this is a step towards helping them aggregate more of it.”

CNBC also reported that Gadelrab said such a database “might help 23andMe provide people with information about their risks for complex, chronic ailments like diabetes, where it’s helpful for scientists to access a data-set that incorporates information about individual health habits, medications, family history and more.”

Of course, it bears saying that the revenue generated from cornering the market on combined medical, pharmaceutical, and genetic data from upwards of 10-million customers would be a sizable boon to the genetic test company.

CNBC reported that “the company confirmed that it’s a beta program that will be gradually rolled out to all users but declined to comment further on its plans. The service is still being piloted, said a person familiar with the matter, and the product could change depending on how it’s received.”

Will 23andMe Have to Take on Apple?

23andMe already earns a large portion of its revenue through research collaborations with pharmaceutical companies, and it hopes to leverage those collaborations to produce new drug therapies, CNBC reported.

This new venture, however, brings 23andMe into competition with Apple on providing a centralized location from where consumers can access and share their health data. But it also adds something that Apple does not have—genetic data that can provide insight into consumers’ predispositions to certain diseases, which also can aid in the development of precision medicine treatments for those diseases.

Whether Apple Healthcare perceives 23andMe’s encroachment on the health data market as a threat remains to be seen.

Nevertheless, this is another example of a prominent company attempting to capitalize on marketable customer information. Adding medical information to its collected genetic data could position 23andMe to generate significant revenue by selling the merged data to pharmaceutical companies and diagnostics developers, while also helping patients easily access and share their data with healthcare providers. 

It’s a smart move, and those clinical laboratory executives developing ways to produce revenue from their lab organization’s patient lab test data will want to watch closely as 23andMe navigates this new market.

—JP Schlingman

Related Information:

23andMe is Moving into Apple’s Territory with a Pilot to Pull in Medical Data, Not Just DNA

23andMe Venturing onto Apple’s Turf with Health Data Collection

Give All the Data

23andMe Already Has Millions of People’s DNA. Now It Wants Their Health Data Too.

23andMe Wants to Collect Users’ Medical Data, Stepping into Apple’s Territory

Apple Updates Its Mobile Health Apps, While Microsoft Shifts Its Focus to Artificial Intelligence. Both Will Transform Healthcare, But Which Will Impact Clinical Laboratories the Most?

Apple’s Update of Its Mobile Health App Consolidates Data from Multiple EHRs and Makes It Easier to Push Clinical Laboratory Data to Patients

Apple May Be Developing Mobile Device Technology to Monitor User’s Health and Transmit Data in Real Time

Industry analysts speculate that Apple might be planning to enter the EHR and healthcare related markets by transforming mobile technologies into gateway devices connected to providers’ EHR systems and patient data

Imagine a mobile device that monitors vitals while connected in real-time to healthcare providers, electronic health records (EHR), and clinical laboratories. One that measures the physical condition and emotional state of the user by casting light onto skin, and then records and transmits it with a swipe of the touch screen. Would such an innovation change how patients expect to interact with their providers? And how physicians, anatomic pathologists, and medical laboratories receive data from their patients? Certainly.

This is why US patents recently granted to Apple have caught the attention of industry analysts. Some speculate that the tech giant is planning to enter the mobile healthcare monitoring device, EHR, and healthcare data storage markets, as reported at Becker’s Health IT and CIO Review and Patently Apple.

How this would affect medical laboratories and anatomic pathology groups remains to be seen. But where Apple goes, industries follow. Thus, it’s worth following the company’s activities in the healthcare market.

Bringing Clinical Data, Medical Laboratory Test Results, to iPhone

Mobile devices launched the era of consumer-grade fitness wearables. It’s not uncommon for a smart phone or watch to capture and store a range of health data generated by users. This can include everything from heart rate and sleeping patterns to dietary logs and fertility tracking. But, to date, much of that healthcare data is user generated and does not integrate in any meaningful way with the majority of EHR systems. Nor does it enable communications with primary care providers or diagnostic services—such as medical laboratories or pathology groups.

This may soon change.

According to a CNBC report, a unit at Apple is “in talks with developers, hospitals, and other industry groups about bringing clinical data—such as detailed lab results and allergy lists—to the iPhone, according to a half-dozen people familiar with the team.”

The report states that Apple:

·       “Wants the iPhone to become the central bank for health information;

·       “Is looking to host clinical information, such as labs and allergy lists, and not just wellness data; and,

·       “Is talking with hospitals, researching potential acquisitions, and attending health IT industry meetings.”

Christina Farr, the report’s author, predicts that Apple could be preparing to apply its music industry model to the healthcare industry by, “Replacing CDs and scattered MP3s with a centralized management system in iTunes and the iPod—in the similarly fragmented and complicated landscape for health data.”

Former National Coordinator of Health IT for the Department of Health and Human Services, Farzad Mostashari, MD, ScM, rather enthusiastically noted the significance of the move, stating, “If Apple is serious about this, it would be a big f—ing deal.”

At a special event in September, Apple COO Jeff Williams (above) announced Stanford Medicine’s Apple Heart Study, which uses “data from Apple Watch to identify irregular heart rhythms, including those from potentially serious heart conditions like atrial fibrillation,” and, according to Williams, “notify users.” This is just one of several healthcare-related study collaborations Apple is exploring. It is not known if Apple is looking to collaborate with medical laboratories. (Photo copyright: Apple.)

Apple’s History with Healthcare Related Technology

Taken as a single event, these speculations might not convince industry leaders. However, Apple’s long-term investments and acquisitions show a clear trend toward integrating healthcare data into the Apple ecosystem.

Healthcare IT News noted that from 2014 to 2017 Apple:

·       Unveiled three different APIs—HealthKit, ResearchKit, and CareKit—designed to help capture, analyze, communicate, and integrate healthcare data with the Apple iOS and watchOS ecosystems;

·       Hired several MDs, including: Stephen Friend, MD; Rajiv Kumar, MD; Mike Evans, MD; Ricky Bloomfield, MD; and Sumbul Ahmad Desai, MD; and,

·       Engaged with the Argonaut Project and Health Gorilla (a centralized hub of healthcare data and information) suggesting a shift from wearables and basic device-based biometrics toward in-depth reporting, interoperability, and access to third-party healthcare data repositories—such as those in a person’s EHR or medical laboratory portal.

The Future of EHRs or Another Failed Attempt at Innovation?

Apple isn’t the only company to attempt such a system. Other efforts include Microsoft’s Health Vault and Google’s now shuttered Google Health. Another CNBC article notes that Amazon is also researching healthcare related options. “The new team is currently looking at opportunities that involve pushing and pulling data from legacy electronic medical record systems,” stated Farr. “The group is also exploring health applications for existing Amazon hardware, including Echo and Dash Wand.”

However, where most services fail to gain traction is user engagement. After all, if a system isn’t widely used or fails to offer benefits over existing systems, patients and service providers are not likely to go through the process of switching systems. Speaking with CNBC, Micky Tripathi, President and CEO of the Massachusetts eHealth Collaborative notes, “At any given time, only about 10% to 15% of patients care about this stuff. If any company can figure out engagement, it’s Apple.”

According to comScore, 85.8-million people over the age of 13 already own an iPhone in the US. The upcoming facial recognition features on Apple’s iPhone X might also provide the added security needed for those questioning the safety of their data. Should Apple succeed, communicating data between clinical laboratories, physicians, and patients might be both convenient and fast. More importantly, it might be the universal platform that finally provides health data access across the entire care continuum, while simultaneously improving access to providers and empowering healthcare consumers.

Of course, this is a few years from reality. But, we can speculate … would innovative medical laboratories have their patients’ lab test data hosted in the Cloud in such a way that patients and providers could access it securely, along with other protected clinical records?

Imagine how this would enable patients to have their complete medical record traveling with them at all times.

—Jon Stone

Related Information:

Could Apple Be Taking a Bite Out of EHRs?

Could Amazon or Apple Actually Make a Dent In the EHR Market?

Apple Extends Its Reach into Healthcare

Electronic device that computes health data

Apple Is Quietly Working on Turning Your iPhone Into the One-Stop Shop for All Your Medical Info

Wait! What? Amazon and Apple Eye Building EHRs

Apple Is Working with This Small Start-Up to Change How We Track Our Health

Timeline: How Apple Is Piecing Together Its Secret Healthcare Plan

Amazon Has a Secret Health Tech Team Called 1492 Working on Medical Records, Virtual Doc Visits

With Apple Consulting Argonaut Project on Health Records, Interoperability Could Get the Push It Needs

Apple Enlists Help of Startup Health Gorilla to Add Diagnostic Data to iPhones

Apple Designs New App to Allow Use of iPhones to Recruit and Track Patients in Clinical Study as One Strategy to Become a Player in Healthcare Big Data

Researchers, including pathologists, can use Apple’s ResearchKit app to help collect and share genetic information about cancers and other diseases while building a huge genome database

By providing tools to allow users to be more productive in working with healthcare big data, several Silicon Valley giants hope to increase their presence in medical services. The latest company to enter the field is Apple Computers (NASDAQ:AAPL). In March it announced the availability of ResearchKit, an open-source software framework that turns the iPhone into a research tool.

Pathologists and clinical laboratory scientists have a stake in the healthcare big data trend, since more than 70% of the typical patient’s permanent medical record consists of medical laboratory test data. Thus, the products introduced by Apple, Google, and other Silicon Valley firms that are designed to help physicians and other professionals work with healthcare big data have the potential to transform the way value is harvested from these data sets.

It was Google (NASDAQ:GOOG) that took the first leap into the medical research arena. Last year, it launched Google X Life Sciences to assemble a database of the human genome. (See Dark Daily, “Google Takes First Steps to Create World’s Largest Human Genome Database as Part of Wider Strategy to Become a Major Player in Healthcare ‘Big Data’” October 14, 2014).

Apple’s strategy is to support researchers. Its ResearchKit is designed to be an open-source software framework that turns the iPhone into a research tool. It enables development of apps that help medical researchers recruit study subjects and collect health information through iPhone’s sensors and surveys. Because it is an open-source platform, researchers also can create apps for Android and Windows devices. (more…)

;